About Maria Martinez-Lage Alvarez, MD

Dr. Martinez-Lage received her medical degree from the University of Cantabria in Santander, Spain, and completed residency training in Neurology at the Hospital de la Santa Creu i Sant Pau in Barcelona, Spain. She then decided to pursue a career in Pathology and completed Anatomic Pathology and Neuropathology training, followed by a fellowship in selective Surgical Pathology at the University of Pennsylvania in Philadelphia, where she stayed as Assistant Professor following her training. In 2016 Dr. Martinez-Lage joined the Pathology Service at Massachusetts General Hospital. She has participated in Neuropathology education at diverse national venues such as the ASCP and the USCAP annual meetings, and is a member of the AANP (American Association of Neuropathologists) Education Committee. Her research interests focus on the morphological and molecular diagnosis as well as the immunological microenvironment of brain tumors and other disorders of the nervous system, with an emphasis on translational and clinical applications.


Departments, Centers, & Programs:

Clinical Interests:




Mass General Pathology
55 Fruit St.
Boston, MA 02114
Phone: 617-643-0800

Medical Education

  • MD, University of Cantabria School of Medicine
  • Residency, Hospital de la Santa Creu i Sant Pau
  • Residency, Hospital of the University of Pennsylvania
  • Fellowship, Hospital de la Santa Creu i Sant Pau
  • Fellowship, Hospital of the University of Pennsylvania
  • Fellowship, Hospital of the University of Pennsylvania

American Board Certifications

  • Anatomic Pathology, American Board of Pathology
  • Neuropathology, American Board of Pathology

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Current and recent projects include:

  • Study on the immune microenvironment of glioblastoma, and its relationships with survival, molecular subtypes, and other clinicopathological characteristics
  • Analysis of the molecular milieu of glioblastoma in the clinical setting, using next generation sequencing to assess the frequency of coexisting mutations in glioblastoma and their impact in clinical trial selection and therapy guidance
  • Neuropathological aspects of early clinical trials on investigational cell therapy using patients’ own T-cells (CAR-T) modified to recognize EGFRvIII, a mutation seen in glioblastoma
  • Neuropathological correlates of specific MRI parameters in the differentiation of recurrence versus treatment-related changes (“pseudo-progression”) in patients with glioblastoma
  • Pathological assessment of an animal model of glioma to assess key aspects of gliomagenesis, tumor stem cell characteristics, and aggressiveness.
  • Evaluation of the interaction of novel immune therapies with the central and peripheral nervous system
  • Investigation of molecular markers involved in the underlying mechanisms of meningioma progression and meningioma aggressiveness
  • Examination of certain morphological, immunohistochemical, and clinical aspects of pituitary adenomas.


Reviews: Comments and Ratings